Immunotherapy window before chemo tested in aggressive breast cancer
NCT ID NCT04770272
First seen Jan 12, 2026 · Last updated May 15, 2026 · Updated 22 times
Summary
This study looked at whether giving a two-week 'window' of the immunotherapy drug atezolizumab alone before starting chemotherapy could improve outcomes for people with triple-negative breast cancer. The trial enrolled 442 participants and compared this approach to starting atezolizumab and chemotherapy together from the beginning. The study was terminated early, but its goal was to find better ways to shrink tumors before surgery and identify which patients benefit most from this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Marienhospital Bottrop gGmbH; Klinik für Frauenheilkunde und Geburtshilfe;
Bottrop, 46236, Germany
Conditions
Explore the condition pages connected to this study.